« February 2007 | Main | April 2007 »

Mar30
Tequila Raw Ingredient as Drug-carrier for Therapeutics against Colon Diseases

Blue agave is a fruit used to make tequila. Natural compounds from this fruit have been found in earlier laboratory studies to be potentially effective in the delivery of drugs to the colon than conventional drug-carriers.

Such were the findings of chemists at the University of Guadalajara in Mexico which could lead to improved treatments for ulcerative colitis, irritable bowel syndrome, cancer, Crohn's disease and other colon diseases.

jose_cuervo_tequila.jpgAccording to the study’s researchers:

The tequila compounds, a class of polysaccharides known as fructans, were developed by the scientists in Mexico into tiny microspheres that are capable of carrying existing drugs that are used to treat colon diseases.

Because the compounds resist destruction in the stomach, they could allow more of the drugs to reach the colon intact and improve their effectiveness.

The study’s findings have recently been presented at the 233rd national meeting of the American Chemical Society.

Find more details from the full report.

[photo credit: andrew.stottsan.net]

Mar30
Pfizer Initiates Glaucoma Clinical Trial of PF-03187207 under Collaboration with NicOx
Clinical trials for NicOx S.A. (EPA: COX)’s new experimental medicine for the treatment of glaucoma - PF-03187207 - has recently been initiated by Pfizer Inc.  (NYSE: PFE) following USFDA’s approval of its Investigational New Drug (IND) approval for PF-03187207, which... Continue Reading
OseoNews.com: Research on Dental Implants a Click Away
Sponsored Review How do you find information on dental implants when you have no idea where to begin your research? Most of us would simply call the 800 number we know so well, but OsseoNews: Dental Implant News and Discussion... Continue Reading
Mar29
Carrington Laboratories and International Vaccine Institute Collaborates on Sublingual Vaccines
A wholly-owned subsidiary of DelSite Biotechnologies, Inc. – Carrington Laboratories Inc. (Nasdaq: CARN) has entered into a collaborative agreement with the International Vaccine Institute (IVI) to evaluate DelSite's drug delivery technology for sublingual vaccines that can be used for needle-free... Continue Reading
New Long Acting Drug For Erectile Dysfunction: Dong-A PharmTech’s Udenafil, Passed Phase 2b Clinical Trial
Dong-A PharmTech Co., Ltd. (SEO:000640) has recently completed its 340 patient phase 2b "at-home" clinical study for udenafil – the company’s new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED). Udenafil was approved... Continue Reading
Adams Respiratory Therapeutics Collaborates With MonoSol Rx, LLC
A specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARXT) - has entered into a license and collaboration agreement with MonoSol... Continue Reading
StormBio and Imperial Innovations Collaborates on Pandemic Influenza Treatment
StormBio, Inc. and Imperial Innovations Group plc have entered into an agreement to license patents and know-how for development of a novel therapy for life-threatening influenza and other inflammatory diseases. The said agreement allows StormBio to develop a novel therapeutic... Continue Reading
Nuvelo’s rNAPc2 Received USFDA Fast Track Designations as First- and Second-Line Treatment of Metastatic Colorectal Cancer
The USFDA has granted two separate fast track designations to Nuvelo, Inc. (Nasdaq: NUVO)’s product candidate rNAPc2: for first-line treatment of metastatic colorectal cancer (mCRC) to improve progression-free survival and overall survival when added to Avastin®-containing 5-flurourocil (5-FU)-based chemotherapy regimensfor... Continue Reading
REMICADE® Recommended for Approval by EU CHMP for Biologic Treatment of Pediatric Crohn's Disease
Co-developed by Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP), REMICADE® (infliximab) was first approved in the U.S. ( by the USFDA) in 1998 as treatment U.S. for adult Crohn's disease (CD) and later, in 2005, for adult ulcerative colitis. REMICADE®... Continue Reading
Mar27
First Therapeutic Vaccine for Cancer Treatment, Approved by USDA in Canines
The U.S. Department of Agriculture has conditionally approved a novel therapeutic vaccine for the treatment of canine melanoma – a common but deadly form of cancer in dogs. Canine melanoma is an aggressive form of cancer that typically appears in... Continue Reading
New High Blood Pressure Drug Tekturna®, Works Better Adjunct to Diovan®
Tekturna® (aliskiren) and Diovan® (valsartan) are both cardiovascular drugs from Novartis (VTX: NOVN).Tekturna® is the first USFDA-approved direct renin inhibitor which works by directly targeting an enzyme that triggers a process that can lead to high blood pressure, it has... Continue Reading
Schering-Plough and Merck Collaborates to Make New Cholesterol-lowering Drug
Schering-Plough Corporation (NYSE: SGP) has entered into an agreement with Merck & Co., Inc. (NYSE: MRK) to initiate the development of a new cholesterol-lowering drug by combining ezetimibe and atorvastatin. Past collaborations between these two companies created ZETIA® (ezetimibe) and VYTORIN®... Continue Reading
EMEA Recommends Oral Cancer Drug REVLIMID® as Treatment for Multiple Myeloma
The European Medicines Agency (EMEA) has granted a positive opinion on Celgene Corporation (Nasdaq: CELG)’s novel oral cancer drug REVLIMID® (lenalidomide) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least... Continue Reading
Mar26
Manufacturing Agreement with SAFC for Lead anticancer agent Cloretazine® (VNP40101M), Extended by Vion Pharmaceuticals
Vion Pharmaceuticals, Inc. (Nasdaq: VION) has recently extended its manufacturing agreement with SAFC (a member of the Sigma-Aldrich Group) for its lead anticancer agent Cloretazine® (VNP40101M). The extended agreement will allow SAFC to continue the manufacture of Cloretazine® (VNP40101M) active... Continue Reading
Lilly Invests Additional $50 Million to Global Tuberculosis Partnership
In lieu of World TB Day, Eli Lilly and Co. (NYSE: LLY) has announced its plans to invest an additional $50 million in an innovative, global partnership to fight Multi-Drug Resistant Tuberculosis (MDR-TB). According to Sidney Taurel, Lilly's chairman and... Continue Reading
Mild Hyperthermia Enhances Anti-tumor Effects of Alfacell's ONCONASE®
ONCONASE® (ranpirnase), a first-in-class therapeutic based on Alfacell Corporation's proprietary ribonuclease (RNase) technology is a natural protein isolated from the leopard frog, which has been shown (in both laboratory and clinical setting) to target cancer cells while sparing normal cells:... Continue Reading
Study Backs Martek’s life’sDHA™’s Ability to Lower Diastolic Blood Pressure
A study from the King’s College, London has demonstrated the ability of Martek Bioscience’s life’sDHA™ in reduction of diastolic blood pressure in middle-aged subjects. A vegetarian form of DHA omega-3, life'sDHA™ is made from microalgae under tightly controlled manufacturing conditions,... Continue Reading
Mar25
China Biopharma Signed Distribution Agreement with Takeda Pharmaceutical
China Biopharma, Inc. (OTC: CBPC)’s Chinese subsidiary - Hainan CITIC Biopharmaceutical Development Co., Ltd. - has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. (TYO: 4502).As part of Takeda's goal to expand sales channels in Asia, China Biopharma... Continue Reading
Chromos and Pain Thearapeutics Entered into Cell Line Engineering Agreement
Chromos Molecular Systems Inc. (TSE: CHR) has recently entered into an agreement with Pain Therapeutics, Inc. (NASDAQ: PTIE) for the development of a cell line utilizing Chromos' ACE System. Chromos' ACE System is a versatile and potent biological engineering system... Continue Reading
DoD Awarded Grant to Cleveland BioLabs for Development of Radiation Countermeasure Compound, Protectan CBLB502
Cleveland BioLabs, Inc. (Nasdaq: CBLI) has recently received a development fund (between $1.3 and $2.4 million) from Defense Threat Reduction Agency (DTRA) of the Department of Defense (DoD) for the development leading to the acquisition of its radiation countermeasure compound,... Continue Reading
MINRAD’s Sevoflurane, Approved in Japan
MINRAD International, Inc.’s exclusive distribution partner in Japan – Merck Seiyaku – has received marketing approval from Japanese Ministry of Health for Sevoflurane. An interventional pain management company, MINRAD International, Inc. (AMEX: BUF) has real time image guidance and anesthesia... Continue Reading
CTI Filed USFDA SPA for Phase III Trial of XYOTAX™ in Women Lung Cancer
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) has recently filed a Special Protocol Assessment (SPA) to the US FDA for the design of a phase III trial of combination therapy for women with advanced lung cancer. The said trial, known as PGT307, will... Continue Reading
Mar24
Preclinical Data of Amicus Therapeutics’ Plicera™, Promising against Gaucher Disease
Preclinical studies of Amicus Therapeutics (706165)’ Plicera™ (isofagomine tartrate, AT2101) revealed that it can increase levels of the target enzyme in cells derived from a patient with the N370S mutation and in mice that express the L444P mutation – the two... Continue Reading
Promising Research Data Suggest Potential of ImmuneRegen BioSciences’ Homspera™ as Co-therapeutic Agent
Data obtained by ImmuneRegen BioSciences on its Substance P analog – Homspera™ - suggests that the compound has potential value as a co-therapeutic agent or vaccine adjuvant for influenza and acute radiation syndrome therapeutics. The Company believes that, in conjunction... Continue Reading
NOXAFIL® (Posaconazole) is Recommended by New Cancer Practice Guidelines for Antifungal Prophylaxis in Certain High-Risk Patients
NOXAFIL® (posaconazole) Oral Suspension, an antifungal agent by Schering-Plough Corporation (NYSE: SGP) has received a category 1 recommendation (1) (highest rating) for preventing certain invasive fungal infections (IFIs) in high-risk cancer patients and a category 2B recommendation (2) for preventing... Continue Reading
WRAIR and USAMMDA Collaborates with Sigma-Tau Pharmaceuticals for New Treatment for Severe Malaria
A new treatment for severe malaria - Intravenous (IV) Artesunate – will be developed and commercialized under a collaborative research and development agreement between the Walter Reed Army Institute of Research (WRAIR), the U.S. Army Medical Materiel Development Activity (USAMMDA),... Continue Reading
Mar23
Blame it on Grey's Anatomy
Pardon my recent absence in this blog. I wish I could say i was on vacation...well, sort of...because I took a forced blog hiatus for two days and exchanged the internet/blogosphere for two seasons of Grey's Anatomy which I just... Continue Reading
DecisionView Entered Multi-year Agreement with GlaxoSmithKline
Leading developer of innovative software solutions that optimize the business performance of life sciences organizations around the world, DecisionView, Inc. has signed a multi-year agreement with GlaxoSmithKline (NYSE: GSK) for the standardization of DecisionView's StudyManager application for optimizing clinical recruitment... Continue Reading
Mar20
Evotec AG and Boehringer Ingelheim Entered Alzheimer’s Disease Collaboration
Evotec AG (FRA: EVT) has recently entered into a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets as potential points of intervention in the treatment of Alzheimer's disease (AD). The Research Institute of Molecular Pathology in Vienna (IMP)... Continue Reading
University of British Columbia Licensed Clinical Stage Diabetes Therapy to Akesis Pharmaceuticals
Akesis Pharmaceuticals, Inc. (OTC: AKES) has entered into an exclusive license and commercialization agreement with the University of British Columbia for bis(ethylmaltolato) oxovanadium (IV) or BEOV – a novel vanadium compound that has shown potential for the treatment of type... Continue Reading
Medivation, Inc.’s Dimebon™ Passed Efficacy Trial in Alzheimer’s Disease Patients
The top-line positive results of Phase 2 efficacy trial of Dimebon™ in patients with mild-to-moderate Alzheimer's disease have recently been presented by Medivation, Inc. (Amex: MDV) in an oral presentation (abstract #1662) at the 8th International Conference on Alzheimer's and... Continue Reading
Mar18
Micromet and TRACON Pharmaceuticals Entered Exclusive Worldwide License Agreement for the Development and Commercialization of Humanized Antibody against Cancer
Founded in 2005 by Paramount BioSciences, LLC, TRACON Pharmaceuticals is a privately held biopharmaceutical company focused on the development of products for cancer treatment, including agents that inhibit angiogenesis. Micromet, Inc. on the other hand, is a biopharmaceutical company focused... Continue Reading
Exelixis Submitted IND for Candidate Anti-cancer Compound XL147
Exelixis, Inc. (Nasdaq: EXEL) has recently submitted an investigational new drug (IND) application to the USFDA for its candidate anticancer compound XL147. XL147 is a novel, orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). In... Continue Reading
Alexion Pharma’s Soliris™, First Therapy for Paroxysmal Nocturnal Hemoglobinuria (PNH) Approved by the USFDA
The USFDA has recently approved Soliris™ (eculizumab) for the treatment of all patients with paroxysmal nocturnal hemoglobinuria (PNH). A product of Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN), Soliris™ is the first therapy ever approved for PNH and is indicated for the... Continue Reading
Mar17
Abeille Pharma’s Transdermal Patch for Emesis, Licensed to SymBio Pharma for Commercialization in Japan and Pacific Rim Countries
Abeille Pharmaceuticals, Inc. and SymBio Pharmaceuticals have entered into an exclusive license and distribution agreement for the development and marketing of AB-1001 in Japan, China (including Hong Kong), Korea, Taiwan and Singapore. AB-1001 is Abeille's transdermal patch for emesis or... Continue Reading
Aida Pharma Subsidiary Commenced Preclinical Study of Vasostatin-Apo2L, Potential Anti-Cancer Therapy
A subsidiary of China’s Aida Pharmaceuticals, Inc. (OTC: AIDA) - Shanghai Qiaer Biotechnology – has initiated the preclinical research of the company’s potential anti-cancer treatment Vasostatin-Apo2L. A recombinant fusion protein, Vasostatin-Apo2L is a potential tumor growth inhibitor. The treatment may... Continue Reading
GSK Expands Patient Assistance Program to Include Breast Cancer Drug TYKERB®
GlaxoSmithKline’s breast cancer drug TYKERB® has recently been approved by the USFDA for advanced or metastatic breast cancer. In lieu of this approval, GSK confirmed that TYKERB® (lapatinib) will be available through Commitment to Access – the company’s program which... Continue Reading
Mar16
SPA for Phase III Clinical Trial of Pixantrone in non- Hodgkin's Lymphoma (NHL) Submitted by CTI to USFDA
A Special Protocol Assessment (SPA) has been submitted by Cell Therapeutics, Inc. (Nasdaq: CTIC) to the U.S. Food and Drug Administration (FDA) for the design of its phase III trial of pixantrone for patients with indolent non- Hodgkin's lymphoma (NHL).... Continue Reading
Lev Pharmaceuticals’ C1-esterase inhibitor (C1-INH) Passed Pivotal Phase III Trial for Hereditary Angioedema (HAE)
Currently without a USFDA-approved acute therapy in the United States, Hereditary Angioedema (HAE) or hereditary C1-inhibitor deficiency is a rare and life-threatening inflammatory condition characterized by recurrent attacks of inflammation affecting the extremities (the hands and feet), the face, the... Continue Reading
Advanced Life Sciences’ Cethromycin Granted USFDA Orphan Drug Status for Anthrax
The USFDA has granted an Orphan Drug Designation to cethromycin for the prophylactic treatment of patients exposed to inhalation anthrax. Cethromycin - a second generation ketolide antibiotic undergoing Phase III clinical trial for the treatment of respiratory tract infections –... Continue Reading
USFDA Accepted Adams Respiratory Therapeutics' NDA Submission for Prescription Cough Suppressant
The USFDA has recently accepted the New Drug Application (NDA) submitted by Adams Respiratory Therapeutics, Inc. (Nasdaq: ARXT) for 600 mg and 1200 mg oral solid extended release guaifenesin combination products for the prescription treatment of cough. The said NDA... Continue Reading
CeNeRx BioPharma’s Third Generation RIMA Antidepressant -Tyrima® - Passed Phase I Clinical Trial
Tyrima™ - a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A or RIMAs – is CeNeRx BioPharma, Inc.’s lead candidate for the treatment of depression and anxiety passed its first human trial (Phase... Continue Reading
Mar15
Post-Marketing Studies of AMITIZA® Initiated by Sucampo Pharma in Renal or Hepatic Impaired Subjects
A product of Sucampo Pharmaceuticals, Inc. (706843) - AMITIZA® (lubiprostone) – has been approved in January 2006 by the USFDA for the treatment of Chronic Idiopathic Constipation (CIC) in adults. Now, Sucampo has commenced two clinical studies of AMITIZA® (lubiprostone)... Continue Reading
Array BioPharma and VentiRx Pharmaceuticals Entered License Agreement
Array BioPharma Inc. (Nasdaq: ARRY) and VentiRx Pharmaceuticals Inc. have entered into a license agreement granting VentiRx exclusive worldwide rights to Array's Toll-like receptor (TLR) program. According to Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx: "These... Continue Reading
Virax Holdings Licensed Transgene Co-X-Gene™ Technology to Two Transgene Immunotherapeutic Products
Virax Holdings Limited (ASX: VHL) has entered into a license agreement with the French biopharmaceutical company, Transgene S.A. (EPA: TNG) which grants Transgene an exclusive access to Virax's Co-X-Gene™ technology patents for use in two of Transgene's immunotherapeutic products, TG4010... Continue Reading
Mar14
Interesting Finds: Pharma-related Blog Posts 4
Let’s see if today’s blogosphere might interest us pharma blog readers… At Allergizer: First OTC Nasal Sprays for Headache, Allergy and Sinus Relief : Sinol® Nasal Sprays, Launched by STG Media Corp. At Cancer Commentary: Novel Vaccine against Chemo-resistant Ovarian... Continue Reading
Preliminary Results of Chemokine Therapeutics’s CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients, Demonstrated Positive Data
Chemokine Therapeutics Corp. (TSE:CTI) is a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease. CTE- 9908 is the company’s anti-cancer drug candidate - a peptide analog of the Chemokine SDF-1, and an antagonist of its... Continue Reading
Schering-Plough Will Acquire Organon BioSciences
Its Board of Directors has approved Schering-Plough Corporation (NYSE: SGP)’s transaction to acquire Organon BioSciences N.V. - the human and animal health care businesses of Akzo Nobel N.V. (AMS: AKZOY). The said transaction, expected to close by the end of... Continue Reading
Oxford BioMedical Will Acquire Oxxon Therapeutics
Oxxon Therapeutics Limited (7725872) is a private UK-based company developing innovative, antigen-specific immunotherapies to treat patients with cancer and chronic infectious diseases. Based in Oxford, UK, Oxford BioMedica (SEA: OXB) is a publicly traded biopharmaceutical company focused on the development... Continue Reading
Mar12
La Jolla Pharmaceutical’s Riquent® Passed Interim Phase 3 Trial in Lupus Patients
Interim clinical data of La Jolla Pharmaceutical Company (Nasdaq: LJPC)’s ongoing double-blind, placebo-controlled randomized Lupus Phase 3 trial of Riquent® (abetimus sodium) revealed positive antibody results. Analyses of interim antibody data indicate that patients treated with 900 mg or 300... Continue Reading
Supplemental New Drug Application (sNDA) for Pediatric Doses of Tamiflu®, Submitted by Roche to USFDA
Tamiflu® is indicated for the prevention and treatment of influenza types A and B in patients one year and older and is currently available in a 75 mg capsule for adults and as liquid suspension formulation for children. Roche –maker... Continue Reading
Mar 9
Interesting Finds: Pharma-related Blog Posts 3
Once more, here are some pharma-related science/health/medical blog posts that you might find interesting and useful: At Cancer Commentary: Green Tea Polyphenol + COX-2 Inhibitor Can Slow Progression of Prostate Cancer At Diabetes Notes: Depression Treatment May Help Long Term... Continue Reading
Use of InflameAway™-Celadrin® Significantly Improved Knee Function and Joint Mobility
Non-prescription Inflame Away™-Celadrin® is available in two forms: a softgel and a topical cream application. A new clinical study - the fourth clinical study performed on the efficacy of Celadrin® during the past six years – demonstrated that Celadrin® can... Continue Reading
Use of HPV Vaccine, Endorsed by National Medical Association (NMA)
In a statement recently issued by the National Medical Association (NMA), it is encouraging “the appropriate use of the Human Papillomavirus (HPV) vaccine, but believes that patient participation should be voluntary." According to Albert W. Morris, M.D., President of the... Continue Reading
USFDA Approved 5 New Indications of Lipitor® in Heart Disease Patients
Lipitor® Tablets has been approved by the USFDA for the following new indications: to reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain; in patients with... Continue Reading
Novel Cystic Fibrosis Therapy Moli1901, Passed Phase II Clinical Trial
Moli1901, a novel investigative compound for the treatment of cystic fibrosis (CF) is being developed by AOP Orphan Pharmaceuticals AG in Europe under a licensing and commercialization agreement with Lantibio, Inc. The two companies have recently announced the positive final... Continue Reading
Mar 7
LAB International’s Fentanyl TAIFUN® Passed Open-label Phase IIb Trial
Fentanyl TAIFUN® is a fast-acting fentanyl formulation delivered using LAB International Inc. (TSE: LAB)’s TAIFUN® dry powder inhaler platform. The company has recently announced the positive results from its open-label Phase IIb clinical trial of Fentanyl TAIFUN® which demonstrated successful... Continue Reading
Hovione’s Inhaler Technology Licensed to Sankyo and Biota for Influenza Drug Delivery
Hovione LLC (10316445) agreed to license its dry powder inhaler technology, jointly to Sankyo Company Ltd. (TYO: 6417)) and Biota Holdings Ltd. (ASX: BTA) for the delivery of long acting neuraminidase inhibitors (LANI). The long acting neuraminidase inhibitors (LANI) -... Continue Reading
Eli Lilly To Acquire Hypnion, Inc.
A privately held neuroscience drug discovery company focused on sleep disorders – Hypnion, Inc. – has recently signed a definitive merger agreement with Eli Lilly and Company (NYSE: LLY), allowing Lilly to acquire Hypnion. Hypnion stockholders have already approved the... Continue Reading
Phase 3 INSPIRE Trial of Actimmune® in Idiopathic Pulmonary Fibrosis (IPF) Discontinued by Intermune, Inc.
Actimmune® (interferon gamma-1b), under Phase III clinical trial has been found not significantly beneficial in patients with idiopathic pulmonary fibrosis (IPF) compared to placebo – enough for the study’s independent data monitoring committee (DMC) to recommend discontinuation of the trial.The Phase... Continue Reading
Mar 6
Myriad’s Flurizan™ Passed Phase 2 Follow-up Study in Mild Alzheimer's Disease Patients
Clinical data of a completed Phase 2 follow-up study of Flurizan™ in patients with mild Alzheimer's disease indicate that Flurizan may be capable, not only of slowing the decline of Alzheimer's disease, but of halting the disease in its tracks.... Continue Reading
Iomai’s Vaccine Patch for Travelers' Diarrhea, Passed Challenge Study
Enterotoxigenic E. coli (ETEC) bacteria is the most common cause of traveler’s diarrhea (affecting 20-50 % of international travelers to areas where the bacteria is endemic), to which there is no vaccine available in the United States. Currently, to avoid... Continue Reading
Transition Therapeutics’ E1-I.N.T.™ Passed Phase IIa Clinical Trials in Type 1 and Type 2 Diabetes Patients
Phase IIa trials conducted by Transition Therapeutics Inc. (TSE: TTH) for its regenerative product, E1-I.N.T.™, demonstrated safety, efficacy and tolerability in type 1 and type 2 diabetes patients. Data from the trial in type 2 diabetes patients demonstrated that E1-I.N.T.™... Continue Reading
Memory Pharma’s MEM 1003 Failed Phase 2a Bipolar Disorder Clinical Trial
Though found safe and generally well tolerated, Memory Pharmaceuticals Corp. (Nasdaq: MEMY)’s MEM 1003 did not prove effective for the treatment of acute mania in bipolar disorder, as revealed by clinical data from a Phase 2a study supported by the... Continue Reading
Mar 5
Dermatrends, Inc. Partners with Teikoku Pharma USA to Develop Transdermal Formula of Anti-Psychotic Drugs
A drug delivery company - Dermatrends, Inc. – has entered into an agreement with Teikoku Pharma USA (8887877) to develop a prototype patch formulation for the transdermal delivery of a widely used anti-psychotic pharmaceutical compound. The terms of agreement include... Continue Reading
Insert Therapeutics Agreed to Partner with R&D-Biopharmaceuticals To Develop New Anti-Cancer Drugs
A majority-owned subsidiary of Arrowhead Research Corporation (Nasdaq: ARWR) - Insert Therapeutics – has signed a definitive agreement with R&D Biopharmaceuticals in which it will acquire an exclusive, world-wide license to multiple second generation epothilone anticancer drugs. Epothilones are naturally... Continue Reading
PREVENAR™’s Extended Indication to Include Pneumonia and Otitis Media, Received Positive Opinion from EU Committee
The EMEA Committee for Medicinal Products for Human Use (CHMP) has already expressed two positive opinions to Wyeth Pharmaceuticals’ application to extend the indication of PREVENAR™ (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed) to include active immunization against pneumonia and acute otitis... Continue Reading
Pharmion Corp.’s Marketing Authorization Application (MAA) for Thalidomide Pharmion (thalidomide), Accepted by the EMEA
The European Medicines Agency (EMEA) has accepted for review Pharmion Corporation (Nasdaq: PHRM)’s Marketing Authorization Application (MAA) (submitted in January 2007) for Thalidomide Pharmion (thalidomide) for the treatment of untreated multiple myeloma – the second most common cancer of the... Continue Reading
Mar 4
Astellas' Vaprisol®, USFDA-approved for the Treatment of Hypervolemic Hyponatremia
Vaprisol® (conivaptan hydrochloride injection), an arginine vasopressin (AVP) receptor antagonist, has been approved by the USFDA for the intravenous treatment of hypervolemic hyponatremia in hospitalized patients. Discovered and developed by Astellas Pharma, Inc. (TYO: 4503), Vaprisol® is the first drug... Continue Reading
Idenix Pharma’s SEBIVO® (Telbivudine) Approved in China
The Chinese State Food and Drug Administration (SFDA) has recently approved SEBIVO® (Telbivudine) as a once-a-day treatment, taken orally with or without food, for the treatment of chronic hepatitis B (CHB). Telbivudine received regulatory approval in the United States from... Continue Reading
Mar 3
2007 BIO International Convention
What: 2007 BIO International Convention When: May 6-9 2007 Where: Boston Convention & Exhibition Center Boston, Massachusetts, USA 2007 BIO International Convention is the global event for biotechnology. Click here to register. Former award-winning actor, now Parkinson's disease patient advocate... Continue Reading
Mar 2
RISPERDAL®, Granted Pediatric Exclusivity by USFDA
Marketed by Janssen, L. P. (12381409), RISPERDAL® (risperidone) is approved in the United States for the treatment of acute manic or mixed episodes of Bipolar I Disorder and for the treatment of schizophrenia in adults. Also, RISPERDAL® was approved in... Continue Reading
MAP Pharmaceuticals’ Inhaled Migraine Drug Candidate Passed Phase 2 Clinical Trials
MAP Pharmaceuticals’ inhaled migraine drug candidate - Tempo™ - passed two phase 2 clinical trials. The first Phase 2 study demonstrated clinically significant results in a randomized, outpatient, placebo-controlled study at nine U.S. headache centers. In addition, a second Phase... Continue Reading
Mar 1
Over 300 Medicines against Rare Diseases, In Development
Currently, there are over 300 medicines under development to treat or prevent hundreds of rare diseases, as recently reported by the Pharmaceutical Research and Manufacturers of America (PhRMA). The National Institutes of Health estimates that there are approximately 6,000 rare... Continue Reading
Evotec and Interprotein Collaborates to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases
Evotec AG (FRA: EVT) and Interprotein Corporation (previously IntercytoNanoScience Co., Ltd.) have signed a collaboration agreement on Interprotein's Interleukin 6 (IL-6) inhibitors programme for the development of novel, orally active drugs against inflammatory diseases. IL-6 is a crucial cytokine involved... Continue Reading
First Medication for Treatment and Prevention of Vomiting in Dogs, Approved by the USFDA
The USFDA has approved Cerenia™ (maropitant citrate) – a product of Pfizer Animal Health (PAH) - the first medication to prevent and treat acute vomiting in dogs. Vomiting is one of the most common reasons owners take their dogs to... Continue Reading

« February 2007 | Main | April 2007 »

Advertise

Watch the Digital Health Revolution


Related Resources

recent comments

    sponsored ads



    subscribe


    Prefer Email?
    Subscribe below-

    Enter your Email:


    Powered by FeedBlitz What's this?

    Current News

    Support This Blog

    blogroll


    top blogs

    business social media

    Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

    BIZZlogos - Add your logo - free link to your site
    BIZZphotos - Add photos of your products and people
    BIZZprofiles - Submit your profile and build your online visibility
    BIZZspotlight - Spotlight your business with free links
    BIZZvideos - Videos about businesses, products and business people.
    BIZZbites - "Digg" for Business - Submit your articles and posts

    Know More Media - Health Care / Pharmaceutical / Fitness

    know more media network

    View Network Map

    Network Feed List (OPML)

    Know More Media Network
    Feed


    we support unitus

    PRWeb

    Influencer



    PharmaGazette is a member of the Know More Media network of business related blogs.

    Here are some current headlines from some of our business publications:

    ProductivityGoal

    CallCenterScript

    AdHurl

    TheBizofKnowledge

    LandingTheDeal

    CustomersAreAlways

    HealthCareVox

    BrainBasedBusiness

    TheInsurancePolicy

    MarketingBlurb